Between March 1988 and July 1990, 28 adults with chronic myelogenous leukaemia (CML)
were treated with a combination of recombinant human interferon (IFN) alpha‐2b sc (initial …

Eighteen patients with relapse of chronic myelogenous leukemia (CML) after allogeneic
bone marrow transplantation (BMT) were treated with recombinant human alpha 2a …

We treated 114 ph1+ chronic myeloid leukemia (CML) patients, 105 of whom were in
chronic phase (CP) and 9 in accelerated phase (AP), with interferon alpha‐2b (IFN α‐2b) at …

This multicenter randomized phase III study was designed to compare the efficacy and
toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10mg/m2 d1-10) or …

Abstract Abstract 2192 Poster Board II-169 Thanks to its striking effectiveness, imatinib (IM)
is the current standard of therapy in chronic myeloid leukemia (CML). However, Interferon …

Aims. We assessed the long-term outcome of consecutive patients in the chronic phase of
chronic myeloid leukemia (CML) treated with interferon-alpha (INF-α) in Central and …

The interferons (IFN s) are a group of proteins which can exert a wide range of biologie
effects on normal tissue cells, host immune defense cells, and cancer cells [5, 9, 12, 20] …

Interferon-α (IFN-α) therapy was compared with bone marrow transplantation (BMT) in
patients with chronic myelogenous leukemia (CML) in a multicenter, prospective study. Of …

Thirty patients with chronic myeloid leukemia in chronic phase and less than 1 year from
diagnosis were treated with a combination of interferon alfa-2a (IFN) 9 million units daily …

The present retrospective analysis is based on data of 213 patients with chronic myeloid
leukaemia (CML). They were treated with interferon (IFN) α-2C (Berofor®) at daily doses of …